INCI
INCI NAMEv2.0
enkozhja
原料辞典検索/polyacrylate-crosspolymer-6/POLYACRYLATE CROSSPOLYMER-6
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

POLYACRYLATE CROSSPOLYMER-6

標準 INCI 準拠: POLYACRYLATE CROSSPOLYMER-6
粘度調整剤乳化安定剤
[EU CosIng Official Definition] Polyacrylate Crosspolymer-6 is a copolymer of ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate, crosslinked with trimethylolpropane triacrylate
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における POLYACRYLATE CROSSPOLYMER-6 のグローバル配合基準と処方特性とは？

POLYACRYLATE CROSSPOLYMER-6（CAS番号: N/A）は、化粧品処方において主に粘度調整剤, 乳化安定剤として配合される原料です。日本厚労省/JCIA（規制なし）、韓国MFDS（規制なし）、欧州CosIng（規制なし）など6大法域の法定基準下で管理され、通常 0.15–2%（適正安定域 pH 2–8）で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for POLYACRYLATE CROSSPOLYMER-6
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)POLYACRYLATE CROSSPOLYMER-6 (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)POLYACRYLATE CROSSPOLYMER-6
④ 米国一般化粧品 (US PCPC / MoCRA INCI)POLYACRYLATE CROSSPOLYMER-6
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)聚丙烯酸酯交联聚合物-6
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)POLYACRYLATE CROSSPOLYMER-6 (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for POLYACRYLATE CROSSPOLYMER-6
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #3720
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for POLYACRYLATE CROSSPOLYMER-6
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 3%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03561 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 2%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03561 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Aqueous Serum / Ampoulen=52
Min 0.15% · Q1 0.4% · Median 0.6% · Q3 1% · Max 2%
Emulsion / Creamn=76
Min 0.15% · Q1 0.3% · Median 0.5% · Q3 0.8% · Max 1.5%
Rinse-off Cleansern=10
Min 0.1% · Q1 0.525% · Median 1.25% · Q3 1.5% · Max 3%
Sunscreen / Colorn=5
Min 0.4% · Q1 0.4% · Median 0.8% · Q3 1.5% · Max 1.5%
Aqueous Serum / Ampoule — Electrolyte-resistant thickener & spicule suspension matrix
Verified Source: SEPPIC SEPIMAX ZEN Technical Data Sheet & CN IECIC (cn_iecic_2025) · SEPPIC 44 · Evonik 8
Typical Median: 0.6%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for POLYACRYLATE CROSSPOLYMER-6
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 A — 水성化粧水・美容液・アンプル0.15% · 0.4% · 0.6% · 1% · 2%Electrolyte-resistant thickener & spicule suspension matrixSEPPIC SEPIMAX ZEN Technical Data Sheet & CN IECIC
剤形群 B — 乳液・エマルジョン・クリーム0.15% · 0.3% · 0.5% · 0.8% · 1.5%Low-pH & high-electrolyte emulsion stabilizerSEPPIC SEPIMAX ZEN TDS & CN IECIC
剤形群 C — 洗い流し用クレンザー・シャンプー0.1% · 0.525% · 1.25% · 1.5% · 3%Rinse-off cleanser & surfactant system modifierGlobal Starter Formulation Library Statistical Distribution (n=10, SEPPIC 10)
剤形群 D — 日焼け止め (UV)・メイクアップ・ファンデーション0.4% · 0.4% · 0.8% · 1.5% · 1.5%Sun care & color cosmetics dispersion / sensory modifierGlobal Starter Formulation Library Statistical Distribution (n=5, SEPPIC 5)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water and glycol dispersible (pre-neutralized powder)
Optimal Formulation pH Stability Window (0–14)pH 2.0 – 8.0
0245.5791114

Outside pH 2–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 80°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 80°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ HYDROLYZED SPONGE+ ASCORBIC ACID+ TRANEXAMIC ACID+ GLYCOLIC ACID+ SALICYLIC ACID✕ Excessive dosage (>1…POLYACRYLATE CROSS…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ HYDROLYZED SPONGE+ ASCORBIC ACID+ TRANEXAMIC ACID+ GLYCOLIC ACID+ SALICYLIC ACID
代表商品名参考 (商標法第90条第1項第2号 記述的表示)
SEPIMAX™ ZEN

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: POLYACRYLATE CROSSPOLYMER-6 | CAS No.: N/A | EC No.: N/A - Origin: SYNTHETIC | Functions: , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: anionic | CosIng/MFDS - Official Regional Label Names: US [POLYACRYLATE CROSSPOLYMER-6] · EU [POLYACRYLATE CROSSPOLYMER-6] · CN [聚丙烯酸酯交联聚合物-6] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Polyacrylate Crosspolymer-6 is a copolymer of ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate, crosslinked with trimethylolpropane triacrylate Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3720 (聚丙烯酸酯交联聚合物-6)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 3.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 2.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [aqueous_serum] Typical range: 0.15 ~ 2.0% (Median 0.6%, Ref: SEPPIC SEPIMAX ZEN Technical Data Sheet & CN IECIC) — Electrolyte-resistant thickener & spicule suspension matrix - [emulsion_cream] Typical range: 0.15 ~ 1.5% (Median 0.5%, Ref: SEPPIC SEPIMAX ZEN TDS & CN IECIC) — Low-pH & high-electrolyte emulsion stabilizer - [cleanser_rinse] Typical range: 0.1 ~ 3.0% (Median 1.25%, Ref: Global Starter Formulation Library Statistical Distribution (n=10, SEPPIC 10)) — Rinse-off cleanser & surfactant system modifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Oil Phase dispersion - Optimal pH Range: pH 2.0 ~ 8.0 | Max Process Temp: Max 80°C | Electrolyte Tolerance: HIGH - Incompatibility / Caution: Excessive dosage (>1.2% alone) may cause slight stringiness or pilling; blend with 0.05~0.1% Xanthan Gum for optimal break - Synergy Pairings: HYDROLYZED SPONGE, ASCORBIC ACID, TRANEXAMIC ACID, GLYCOLIC ACID, SALICYLIC ACID | Reference Trade Names: SEPIMAX™ ZEN ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 41471047 (2025, Pharmaceutics): Interfacial Molecular Interactions as Determinants of Nanostructural Preservation in Ibuprofen-Loaded Nanoemulsions and

関連査読付き学術論文 (NIH PubMed) (1)

Interfacial Molecular Interactions as Determinants of Nanostructural Preservation in Ibuprofen-Loaded Nanoemulsions and Nanoemulsion Gels [PMID: 41471047 · 2025]
To&#x161;i&#x107; A, Randjelovi&#x107; D, Ivkovi&#x107; B, Gledovi&#x107; A, Stankovi&#x107; T, &#x110;okovi&#x107; J, Papadimitriou V, Ili&#x107; T, Savi&#x107; SD, Panteli&#x107; I · Pharmaceutics (2025)

Background/Objectives : Nanoemulsions (NEs) are highly promising drug delivery systems that can be made user-friendlier by thickening to nanoemulsion gels (NEGs). However, in order to be regulatory accepted, such a transformation requires systematic understanding of the underlying interactions and stabilization mechanisms, especially when the incorporated active pharmaceutical ingredient may infiltrate the stabilizer layer. Methods : NEs with/without ibuprofen were submitted through direct vs. indirect gelation using three different gelling agents (carbomer 980, xanthan gum, or polyacrylate crosspolymer-6). Multi-technique characterization was employed to demonstrate nanoparticle preservation within the gel networks, a point often neglected when studying nanogels. Results : The nanoemulsion with the most favorable properties (55.07 &#xb1; 0.82 nm, PDI 0.075 &#xb1; 0.022) was successfully transformed into nanoemulgels with all three gelling agents, both by an indirect and direct approach. The combination of Fourier-transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) revealed complex interactions and electron paramagnetic resonance spectroscopy (EPR)-discerned localization of the small-molecule model drug within the surfactants/co-solvents' microenvironment, while atomic force microscopy (AFM) successfully visualized nanodroplets, with or without the presence of aggregates originating from the applied gelling agent. Conclusions : A series of complementary techniques confirmed the preservation of nanodroplets after transformation while highlighting the potential of novel polyacrylate crosspolymer-6 to produce robust gel network while effectively increasing zeta potential from -11.07 to -30.5 mV and allowing for satisfactory ibuprofen release from nanoparticles.

よくある質問 (FAQ)

Q1. POLYACRYLATE CROSSPOLYMER-6 の各国公式全成分表示名称（7トラック）はどのように異なりますか？
日本化粧品工業連合会(JCIA)表示名称は 'POLYACRYLATE CROSSPOLYMER-6 (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'POLYACRYLATE CROSSPOLYMER-6'、中国NMPA IECIC標準中国語名は '聚丙烯酸酯交联聚合物-6' です。
Q2. POLYACRYLATE CROSSPOLYMER-6 のグローバル6大法域における法定配合基準 (Layer 1) は？
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における POLYACRYLATE CROSSPOLYMER-6 の通常配合濃度 (Layer 3) と適正 pH は？
主要剤形 (aqueous_serum) において通常 0.15〜2%（中央値 0.6%）で配合され、適正pH範囲は 2〜8 です。
Q4. POLYACRYLATE CROSSPOLYMER-6 の配合禁忌 (Incompatibilities) と推奨シナジー成分は？
推奨シナジーペアは HYDROLYZED SPONGE, ASCORBIC ACID, TRANEXAMIC ACID, GLYCOLIC ACID, SALICYLIC ACID、配合上の注意点は Excessive dosage (>1.2% alone) may cause slight stringiness or pilling; blend with 0.05~0.1% Xanthan Gum for optimal break です。